Jagsonpal Pharmaceuticals Ltd Falls to 52-Week Low of Rs.158.5

Stock Performance and Price Movement

On 22 Jan 2026, Jagsonpal Pharmaceuticals Ltd recorded an intraday low of Rs.158.5, representing a 4.08% drop for the day and a 3.96% decline compared to the previous close. This marks the lowest price level the stock has reached in the past year, down sharply from its 52-week high of Rs.301.8. The stock has been on a consistent downtrend, falling for six consecutive trading sessions and delivering a cumulative return of -12.61% over this period.

The stock’s current price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum. This technical positioning indicates that the stock remains under pressure in both the short and long term.

Relative Market Context

While Jagsonpal Pharmaceuticals Ltd has been declining, the broader market has shown mixed signals. The Sensex opened higher at 82,459.66 points, gaining 0.67% at the start of the day, though it currently trades slightly lower at 82,368.04, still up 0.56% on the day. The Sensex remains 4.6% below its 52-week high of 86,159.02 but has experienced a three-week consecutive fall, losing 3.96% in that span. Mid-cap stocks have been leading gains, with the BSE Mid Cap index rising 1.18% today, contrasting with Jagsonpal’s underperformance.

Over the past year, Jagsonpal Pharmaceuticals Ltd’s stock has declined by 31.00%, significantly lagging the Sensex’s positive 7.80% return. This divergence highlights the stock’s relative weakness within the market and its sector.

Financial Metrics and Valuation

Jagsonpal Pharmaceuticals Ltd’s financial profile presents a mixed picture. The company reported flat results in December 2025, which has contributed to the cautious sentiment. Despite this, the company’s return on equity (ROE) stands at a respectable 17%, indicating moderate profitability relative to shareholder equity.

However, the stock’s valuation appears expensive on a price-to-book (P/B) basis, trading at 4.3 times book value. This is notable given the stock’s recent price decline and contrasts with its peers’ average historical valuations, where Jagsonpal currently trades at a discount. The company’s price-to-earnings growth (PEG) ratio is 0.4, reflecting earnings growth of 60.3% over the past year despite the stock’s negative price performance.

Debt levels remain low, with an average debt-to-equity ratio of zero, underscoring a conservative capital structure and limited financial leverage.

Shareholding and Market Perception

Domestic mutual funds hold no stake in Jagsonpal Pharmaceuticals Ltd, which is notable given their capacity for detailed research and due diligence. This absence of institutional ownership may reflect reservations about the stock’s valuation or business prospects at current price levels.

The company’s Mojo Score stands at 31.0, with a Mojo Grade of Sell, downgraded from Hold on 3 Nov 2025. This rating reflects the stock’s underperformance and the cautious outlook from the analytical framework used.

Long-Term and Sectoral Performance

Jagsonpal Pharmaceuticals Ltd has underperformed not only in the recent year but also over longer periods. It has lagged the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in delivering returns relative to the broader market.

The Pharmaceuticals & Biotechnology sector, to which Jagsonpal belongs, has seen mixed performance, with some mid-cap stocks leading gains. Jagsonpal’s underperformance relative to its sector peers further highlights the stock’s current difficulties.

Summary of Key Data Points

To summarise, Jagsonpal Pharmaceuticals Ltd’s stock has reached a 52-week low of Rs.158.5, down from a high of Rs.301.8 within the last year. The stock has declined by 31.00% over the past 12 months, underperforming the Sensex by nearly 39 percentage points. The company’s financials show a ROE of 17%, a P/B ratio of 4.3, and a PEG ratio of 0.4, with profits rising 60.3% despite the stock’s price weakness. The absence of domestic mutual fund holdings and a recent downgrade to a Sell grade reflect the cautious stance on the stock.

Jagsonpal’s low debt levels and moderate profitability contrast with its price performance, which remains subdued amid broader market volatility and sectoral pressures.

Market Outlook and Positioning

While the broader market indices have shown resilience, Jagsonpal Pharmaceuticals Ltd’s stock continues to face downward pressure. The stock’s technical indicators and valuation metrics suggest that it remains in a challenging phase relative to its sector and market benchmarks.

Investors and market participants will be closely monitoring the company’s forthcoming financial disclosures and sector developments to gauge any shifts in momentum or valuation trends.

Unlock special upgrade rates for a limited period. Start Saving Now →